NIKKEI 225
38,613.26 -19.76 (-0.05%) HANG SENG
18,061.84 -273.48 (-1.49%) CRUDE OIL
82.34 +0.17 (+0.21%) GOLD FUTURES
2,378.60 +9.60 (+0.41%) DOW
39,134.76 +299.90 (+0.77%) Bitcoin GBP
51,031.94 -688.19 (-1.33%)
NBIX Dec 2024 95.000 call
| Previous close | 26.40 |
| Open | 26.40 |
| Bid | 23.70 |
| Ask | 25.70 |
| Strike | 95.00 |
| Expiry date | 2024-12-20 |
| Day's range | 26.40 - 26.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
Investor's Business DailyNeurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences continues to put up really healthy numbers, with an ostensible 335% profit hike on a powerful reversal last quarter. On Friday, Neurocrine Biosciences stock got a Relative Strength (RS) Rating upgrade from 77 to 82. The upgraded 82 RS Rating means Neurocrine Biosciences stock is among the top 18% overall for price performance over the past year.
Simply Wall St.Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...
PR NewswireNeurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Diurnal Ltd., a Neurocrine Biosciences company, presented information from its neuroendocrinology pipeline at the Endocrine Society Annual Meeting, ENDO 2024, including primary data just published in The New England Journal of Medicine from its CAHtalyst™ Phase 3 registrational studies of crinecerfont in pediatric and adult patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. In addition, Neurocrine Biosciences prese
